Exclusive Summary

• - Originator launched in US/EU in 2016; data exclusivity has ended in major markets, while generic injections remain limited, creating first-mover distribution opportunities.
• - Around 50 million people live with epilepsy globally, ~60% have focal seizures and ≥9 million need add-on therapy, with steady hospital demand for IV antiseizure medications.
• - Brivaracetam is a high-affinity SV2A ligand with rapid IV onset and easier switching, offering fewer behavioral adverse effects than levetiracetam for LEV-intolerant patients.
• - Competition is mainly originator and LEV/other IV AEDs; oral generics are common but injectable generics are scarce, enabling differentiation in hospital channels.
• - Parenteral solution can qualify for biowaiver in many jurisdictions; room-temperature stability and CTD dossier facilitate fast registration and cross-border distribution, with clear price discount versus originator.